Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer

Jackson E. Fowler, James E. Gottesman, C. Fredric Reid, Gerald L. Andriole, Mark S. Soloway

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: We evaluated the pharmacokinetics, safety and efficacy of the implantable Viadurdagger leuprolide delivery system during 12 months in patients with advanced prostate cancer. Materials and Methods: Our open label, multicenter, dose ranging study was done in 2 phases. The treatment phase was a stratified, randomized, parallel evaluation of the safety and efficacy of 1 or 2 implants. The safety extension phase assessed the long-term safety and efficacy of 1 implant. Implant insertion and removal, pharmacokinetic profile and patient satisfaction were also evaluated. The primary efficacy parameter was testosterone suppression for 12 months but luteinizing hormone and prostate specific antigen were also evaluated. Results: Of the 51 patients 27 received i and 24 received 2 implants, of whom 49 completed the 12-month treatment phase. Steady serum leuprolide concentration was maintained from day 3 through the remainder of the 12-month treatment phase and for 2 months after reimplantation. Implantation and reimplantation were well tolerated and acceptable to physicians and patients. Testosterone suppression to the castrate range was 100% in each group. At 12 months mean prostate specific antigen decreased from a baseline of approximately 84% and 91% in groups 1 and 2, respectively. Serious adverse events during the study period in 15 patients were not attributable to treatment. Conclusions: The implantable leuprolide delivery system provides effective suppression of testosterone in patients with advanced prostate cancer.

Original languageEnglish
Pages (from-to)730-734
Number of pages5
JournalJournal of Urology
Volume164
Issue number3 I
StatePublished - Sep 1 2000
Externally publishedYes

Fingerprint

Leuprolide
Prostatic Neoplasms
Safety
Testosterone
Replantation
Prostate-Specific Antigen
Pharmacokinetics
Therapeutics
Luteinizing Hormone
Patient Satisfaction
Physicians
Serum

Keywords

  • Drug implants
  • Leuprolide
  • Prostate
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Fowler, J. E., Gottesman, J. E., Reid, C. F., Andriole, G. L., & Soloway, M. S. (2000). Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. Journal of Urology, 164(3 I), 730-734.

Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. / Fowler, Jackson E.; Gottesman, James E.; Reid, C. Fredric; Andriole, Gerald L.; Soloway, Mark S.

In: Journal of Urology, Vol. 164, No. 3 I, 01.09.2000, p. 730-734.

Research output: Contribution to journalArticle

Fowler, JE, Gottesman, JE, Reid, CF, Andriole, GL & Soloway, MS 2000, 'Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer', Journal of Urology, vol. 164, no. 3 I, pp. 730-734.
Fowler JE, Gottesman JE, Reid CF, Andriole GL, Soloway MS. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. Journal of Urology. 2000 Sep 1;164(3 I):730-734.
Fowler, Jackson E. ; Gottesman, James E. ; Reid, C. Fredric ; Andriole, Gerald L. ; Soloway, Mark S. / Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. In: Journal of Urology. 2000 ; Vol. 164, No. 3 I. pp. 730-734.
@article{9d69b5f66acf427aa53adb313482286c,
title = "Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer",
abstract = "Purpose: We evaluated the pharmacokinetics, safety and efficacy of the implantable Viadurdagger leuprolide delivery system during 12 months in patients with advanced prostate cancer. Materials and Methods: Our open label, multicenter, dose ranging study was done in 2 phases. The treatment phase was a stratified, randomized, parallel evaluation of the safety and efficacy of 1 or 2 implants. The safety extension phase assessed the long-term safety and efficacy of 1 implant. Implant insertion and removal, pharmacokinetic profile and patient satisfaction were also evaluated. The primary efficacy parameter was testosterone suppression for 12 months but luteinizing hormone and prostate specific antigen were also evaluated. Results: Of the 51 patients 27 received i and 24 received 2 implants, of whom 49 completed the 12-month treatment phase. Steady serum leuprolide concentration was maintained from day 3 through the remainder of the 12-month treatment phase and for 2 months after reimplantation. Implantation and reimplantation were well tolerated and acceptable to physicians and patients. Testosterone suppression to the castrate range was 100{\%} in each group. At 12 months mean prostate specific antigen decreased from a baseline of approximately 84{\%} and 91{\%} in groups 1 and 2, respectively. Serious adverse events during the study period in 15 patients were not attributable to treatment. Conclusions: The implantable leuprolide delivery system provides effective suppression of testosterone in patients with advanced prostate cancer.",
keywords = "Drug implants, Leuprolide, Prostate, Prostatic neoplasms",
author = "Fowler, {Jackson E.} and Gottesman, {James E.} and Reid, {C. Fredric} and Andriole, {Gerald L.} and Soloway, {Mark S.}",
year = "2000",
month = "9",
day = "1",
language = "English",
volume = "164",
pages = "730--734",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer

AU - Fowler, Jackson E.

AU - Gottesman, James E.

AU - Reid, C. Fredric

AU - Andriole, Gerald L.

AU - Soloway, Mark S.

PY - 2000/9/1

Y1 - 2000/9/1

N2 - Purpose: We evaluated the pharmacokinetics, safety and efficacy of the implantable Viadurdagger leuprolide delivery system during 12 months in patients with advanced prostate cancer. Materials and Methods: Our open label, multicenter, dose ranging study was done in 2 phases. The treatment phase was a stratified, randomized, parallel evaluation of the safety and efficacy of 1 or 2 implants. The safety extension phase assessed the long-term safety and efficacy of 1 implant. Implant insertion and removal, pharmacokinetic profile and patient satisfaction were also evaluated. The primary efficacy parameter was testosterone suppression for 12 months but luteinizing hormone and prostate specific antigen were also evaluated. Results: Of the 51 patients 27 received i and 24 received 2 implants, of whom 49 completed the 12-month treatment phase. Steady serum leuprolide concentration was maintained from day 3 through the remainder of the 12-month treatment phase and for 2 months after reimplantation. Implantation and reimplantation were well tolerated and acceptable to physicians and patients. Testosterone suppression to the castrate range was 100% in each group. At 12 months mean prostate specific antigen decreased from a baseline of approximately 84% and 91% in groups 1 and 2, respectively. Serious adverse events during the study period in 15 patients were not attributable to treatment. Conclusions: The implantable leuprolide delivery system provides effective suppression of testosterone in patients with advanced prostate cancer.

AB - Purpose: We evaluated the pharmacokinetics, safety and efficacy of the implantable Viadurdagger leuprolide delivery system during 12 months in patients with advanced prostate cancer. Materials and Methods: Our open label, multicenter, dose ranging study was done in 2 phases. The treatment phase was a stratified, randomized, parallel evaluation of the safety and efficacy of 1 or 2 implants. The safety extension phase assessed the long-term safety and efficacy of 1 implant. Implant insertion and removal, pharmacokinetic profile and patient satisfaction were also evaluated. The primary efficacy parameter was testosterone suppression for 12 months but luteinizing hormone and prostate specific antigen were also evaluated. Results: Of the 51 patients 27 received i and 24 received 2 implants, of whom 49 completed the 12-month treatment phase. Steady serum leuprolide concentration was maintained from day 3 through the remainder of the 12-month treatment phase and for 2 months after reimplantation. Implantation and reimplantation were well tolerated and acceptable to physicians and patients. Testosterone suppression to the castrate range was 100% in each group. At 12 months mean prostate specific antigen decreased from a baseline of approximately 84% and 91% in groups 1 and 2, respectively. Serious adverse events during the study period in 15 patients were not attributable to treatment. Conclusions: The implantable leuprolide delivery system provides effective suppression of testosterone in patients with advanced prostate cancer.

KW - Drug implants

KW - Leuprolide

KW - Prostate

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0033883540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033883540&partnerID=8YFLogxK

M3 - Article

VL - 164

SP - 730

EP - 734

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -